MedTrace Logo

Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study

NCT05867160 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-09-10

No results posted yet for this study

Summary

The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.

Conditions

Interventions

OTHER

ASM as adjunctive therapy

ASM approved as adjunctive therapy

Sponsors & Collaborators

  • Hippocrates Research

    collaborator OTHER

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05867160 on ClinicalTrials.gov